A U.S. appeals court on Aug. 26 threw out a $1.2 billion ruling against Gilead Sciences Inc., finding a patent on a cancer therapy the company was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.

A federal appeals court on Aug. 16 revived nearly 6,000 lawsuits alleging that a widely used device produced by 3M Co. to keep surgical patients warm caused them to develop infections.

In a patent infringement lawsuit filed against Eli Lilly, Teva Pharmaceutical won three and lost six patents. The patent lawsuit was over Teva’s Ajovy (fremanezumab-vfrm) to prevent migraines. Eli Lilly has a competitive migraine drug, Emgality (galcanezumab).

A U.S. appeals court on Aug. 10 threw out a price-fixing lawsuit against two Chinese companies that make vitamin C, a case that spotlighted trade tensions between the United States and China.

A federal appeals court upheld a White House-backed rule to require hospitals to disclose the prices they negotiate with insurers for an array of common tests and procedures.

The U.S. Supreme Court agreed to hear a bid by President Donald Trump’s administration to revive pilot programs adopted by the states of Arkansas and New Hampshire that allow work requirements to be imposed on people who receive healthcare under the Medicaid program for the poor.

The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict against Teva Pharmaceutical Industries, ordering the company to pay GlaxoSmithKline $235.5 million in a 13-year-old induced patent infringement case.

A federal appeals court overturned a judge’s approval of a novel plan by lawyers representing cities and counties suing drug companies over the U.S. opioid crisis that would bring every community nationally into their settlement talks.

A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.

A Missouri appeals court rejected Johnson & Johnson’s bid to throw out a jury verdict in favor of women who blamed their ovarian cancer on the company’s baby powder and other talc products, but reduced its damages award to $2.12 billion from $4.69 billion.